Patents by Inventor Roger Strömberg

Roger Strömberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180305404
    Abstract: The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-? peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.
    Type: Application
    Filed: May 15, 2018
    Publication date: October 25, 2018
    Inventors: Roger Strömberg, Dmytro Honcharenko, Jyotirmoy Maity, Alok Juneja, Firoz Roshan Kurudenkandy, Jenny Presto, Lisa Dolfe, André Fisahn, Jan Johansson, Lennart Nilsson
  • Patent number: 10023610
    Abstract: The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-? peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 17, 2018
    Assignee: AlphaBeta AB
    Inventors: Roger Strömberg, Dmytro Honcharenko, Jyotirmoy Maity, Alok Juneja, Firoz Roshan Kurudenkandy, Jenny Presto, Lisa Dolfe, André Fisahn, Jan Johansson, Lennart Nilsson
  • Publication number: 20160340387
    Abstract: The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-? peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 24, 2016
    Inventors: Roger Strömberg, Dmytro Honcharenko, Jyotirmoy Maity, Alok Juneja, Firoz Roshan Kurudenkandy, Jenny Presto, Lisa Dolfe, André Fisahn, Jan Johansson, Lennart Nilsson
  • Patent number: 9463200
    Abstract: The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2? position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 11, 2016
    Assignee: OLIGOMER SCIENCES AB
    Inventors: Roger Strömberg, Dmytro Honcharenko, Stefan Milton
  • Patent number: 9067964
    Abstract: The use of at least one nucleic acid based nuclear localization signal including a natural or synthetic m3G-CAP is shown to increase transmembrane transport of a molecular cargo, in particular large molecules, into the nucleus. The use of natural and synthetic m3G-CAP is disclosed and the effect shown with a natural RNA 5? end nuclear localization signal composed of a 2,2,7-trimethylguanosine CAP (m3G-CAP) coupled to fluorescent Streptavidin in one example, and an antisense oligonucleotide in another. A methylenephosphonate modified m3G-CAP is shown to have improved stability in human serum and in cytosolic extract.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: June 30, 2015
    Assignee: Oligomer Sciences AB
    Inventors: Edvard Smith, Pedro Moreno, Roger Strömberg, Malgorzata Wenska
  • Publication number: 20110306138
    Abstract: The use of at least one nucleic acid based nuclear localization signal including a natural or synthetic m3G-CAP is shown to increase transmembrane transport of a molecular cargo, in particular large molecules, into the nucleus. The use of natural and synthetic m3G-CAP is disclosed and the effect shown with a natural RNA 5? end nuclear localization signal composed of a 2,2,7-trimethylguanosine CAP (m3G-CAP) coupled to fluorescent Streptavidin in one example, and an antisense oligonucleotide in another. A methylenephosphonate modified m3G-CAP is shown to have improved stability in human serum and in cytosolic extract.
    Type: Application
    Filed: December 17, 2009
    Publication date: December 15, 2011
    Inventors: Edvard Smith, Pedro Moreno, Roger Strömberg, Malgorzata Wenska